Small-cell lung cancer: An update on targeted therapies

Research output: Chapter in Book/Report/Conference proceedingChapter

33 Citations (Scopus)

Abstract

Lung cancer is the leading cause of cancer-related deaths world-wide and small-cell lung cancer (SCLC) accounts for up to 25% of lung cancer deaths. There has been a considerable amount of research in the understanding of the depth of biology of SCLC and utilizing this knowledge to develop targeted approaches. The treatment of SCLC remains a challenge, despite remarkable initial efficacy to combination chemotherapy and radiation therapy. The response is usually short-lived and the prognosis of SCLC has not changed over the past few decades, necessitating the critical need for evaluating novel agents/therapies. Several signaling pathways have been found to be activated in SCLC tumor cells, forming a rationale for blocking some of the drugable targets. Molecular changes and biological markers have been identified but remain to be validated. Novel and targeted agents have been evaluated but without much success. Increasing understanding of the biology and potential clinical evaluation of biomarkers will pave the way for more effective treatments.

Original languageEnglish (US)
Title of host publicationImpact of Genetic Targets on Cancer Therapy
EditorsWafik El-Deiry
Pages385-404
Number of pages20
DOIs
StatePublished - Feb 15 2013

Publication series

NameAdvances in Experimental Medicine and Biology
Volume779
ISSN (Print)0065-2598

Fingerprint

Small Cell Lung Carcinoma
Cells
Chemotherapy
Radiotherapy
Biomarkers
Lung Neoplasms
Tumors
Therapeutics
Combination Drug Therapy
Neoplasms
Research

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Joshi, M., Ayoola, A., & Belani, C. (2013). Small-cell lung cancer: An update on targeted therapies. In W. El-Deiry (Ed.), Impact of Genetic Targets on Cancer Therapy (pp. 385-404). (Advances in Experimental Medicine and Biology; Vol. 779). https://doi.org/10.1007/978-1-4614-6176-0-18
Joshi, Monika ; Ayoola, Ayodele ; Belani, Chandra. / Small-cell lung cancer : An update on targeted therapies. Impact of Genetic Targets on Cancer Therapy. editor / Wafik El-Deiry. 2013. pp. 385-404 (Advances in Experimental Medicine and Biology).
@inbook{ed419a48e91e4247bd956e7f14dc41da,
title = "Small-cell lung cancer: An update on targeted therapies",
abstract = "Lung cancer is the leading cause of cancer-related deaths world-wide and small-cell lung cancer (SCLC) accounts for up to 25{\%} of lung cancer deaths. There has been a considerable amount of research in the understanding of the depth of biology of SCLC and utilizing this knowledge to develop targeted approaches. The treatment of SCLC remains a challenge, despite remarkable initial efficacy to combination chemotherapy and radiation therapy. The response is usually short-lived and the prognosis of SCLC has not changed over the past few decades, necessitating the critical need for evaluating novel agents/therapies. Several signaling pathways have been found to be activated in SCLC tumor cells, forming a rationale for blocking some of the drugable targets. Molecular changes and biological markers have been identified but remain to be validated. Novel and targeted agents have been evaluated but without much success. Increasing understanding of the biology and potential clinical evaluation of biomarkers will pave the way for more effective treatments.",
author = "Monika Joshi and Ayodele Ayoola and Chandra Belani",
year = "2013",
month = "2",
day = "15",
doi = "10.1007/978-1-4614-6176-0-18",
language = "English (US)",
isbn = "9781461461753",
series = "Advances in Experimental Medicine and Biology",
pages = "385--404",
editor = "Wafik El-Deiry",
booktitle = "Impact of Genetic Targets on Cancer Therapy",

}

Joshi, M, Ayoola, A & Belani, C 2013, Small-cell lung cancer: An update on targeted therapies. in W El-Deiry (ed.), Impact of Genetic Targets on Cancer Therapy. Advances in Experimental Medicine and Biology, vol. 779, pp. 385-404. https://doi.org/10.1007/978-1-4614-6176-0-18

Small-cell lung cancer : An update on targeted therapies. / Joshi, Monika; Ayoola, Ayodele; Belani, Chandra.

Impact of Genetic Targets on Cancer Therapy. ed. / Wafik El-Deiry. 2013. p. 385-404 (Advances in Experimental Medicine and Biology; Vol. 779).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Small-cell lung cancer

T2 - An update on targeted therapies

AU - Joshi, Monika

AU - Ayoola, Ayodele

AU - Belani, Chandra

PY - 2013/2/15

Y1 - 2013/2/15

N2 - Lung cancer is the leading cause of cancer-related deaths world-wide and small-cell lung cancer (SCLC) accounts for up to 25% of lung cancer deaths. There has been a considerable amount of research in the understanding of the depth of biology of SCLC and utilizing this knowledge to develop targeted approaches. The treatment of SCLC remains a challenge, despite remarkable initial efficacy to combination chemotherapy and radiation therapy. The response is usually short-lived and the prognosis of SCLC has not changed over the past few decades, necessitating the critical need for evaluating novel agents/therapies. Several signaling pathways have been found to be activated in SCLC tumor cells, forming a rationale for blocking some of the drugable targets. Molecular changes and biological markers have been identified but remain to be validated. Novel and targeted agents have been evaluated but without much success. Increasing understanding of the biology and potential clinical evaluation of biomarkers will pave the way for more effective treatments.

AB - Lung cancer is the leading cause of cancer-related deaths world-wide and small-cell lung cancer (SCLC) accounts for up to 25% of lung cancer deaths. There has been a considerable amount of research in the understanding of the depth of biology of SCLC and utilizing this knowledge to develop targeted approaches. The treatment of SCLC remains a challenge, despite remarkable initial efficacy to combination chemotherapy and radiation therapy. The response is usually short-lived and the prognosis of SCLC has not changed over the past few decades, necessitating the critical need for evaluating novel agents/therapies. Several signaling pathways have been found to be activated in SCLC tumor cells, forming a rationale for blocking some of the drugable targets. Molecular changes and biological markers have been identified but remain to be validated. Novel and targeted agents have been evaluated but without much success. Increasing understanding of the biology and potential clinical evaluation of biomarkers will pave the way for more effective treatments.

UR - http://www.scopus.com/inward/record.url?scp=84873603800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873603800&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-6176-0-18

DO - 10.1007/978-1-4614-6176-0-18

M3 - Chapter

C2 - 23288650

AN - SCOPUS:84873603800

SN - 9781461461753

T3 - Advances in Experimental Medicine and Biology

SP - 385

EP - 404

BT - Impact of Genetic Targets on Cancer Therapy

A2 - El-Deiry, Wafik

ER -

Joshi M, Ayoola A, Belani C. Small-cell lung cancer: An update on targeted therapies. In El-Deiry W, editor, Impact of Genetic Targets on Cancer Therapy. 2013. p. 385-404. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4614-6176-0-18